top of page

NDR's TVALA® Trademarked

The lead molecule under development by NDR for treating neuroinflammation is the retro-inverso thymopentin, TVALA®. The application for the novel drug is intended for use in ALS but it may be beneficial in renal dialysis patients as well as for Covid19 infections. TVALA® is the first molecule being developed by NDR. The potential ALS treatment was designed in a program to develop non-hydrolyzing analogs of anti-inflammatory peptides. TVALA® is scheduled for FDA review and into clinical trial less than 24 months after its conception in the laboratory. If successful, NDR may lead the way in shortening the pipeline of treatments to ALS patients by keeping the drug in the not-for-profit space.

92 views0 comments

Recent Posts

See All

Thymosin in the treatment of lung cancer

A new paper authored by Liu and Lu in the Frontiers in Immunology reports the Mechanism and clinical application of thymosin in the treatment of lung cancer. Thymosin is a mixture of peptides obtained

MOLECULAR MECHANISMS OF REDOX REGULATION IN INFLAMMATION

We are hopeful that TVALA will reduce p53 expression in people with ALS. There are two recent publications that give us hope. The first paper is by Maor-Nof et. al. (2022), found in Cell. The found

TVALA Fortune Journal

Pharmacological Characterization of FC-12738: A Novel Retro-Inverso Pentapeptide for Treating Neuroinflammation

bottom of page